Last10K.com

Aveo Pharmaceuticals, Inc. (AVEO) SEC Filing 8-K Material Event for the period ending Monday, March 14, 2022

Aveo Pharmaceuticals Inc

CIK: 1325879 Ticker: AVEO

View differences made from one to another to evaluate Aveo Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aveo Pharmaceuticals Inc.

Continue

Assess how Aveo Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aveo Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Aveo Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits

Ticker: AVEO
CIK: 1325879
Form Type: 8-K Corporate News
Accession Number: 0001628280-22-006051
Submitted to the SEC: Mon Mar 14 2022 4:15:15 PM EST
Accepted by the SEC: Mon Mar 14 2022
Period: Monday, March 14, 2022
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aveo/0001628280-22-006051.htm